Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)
South Korea · Delayed Price · Currency is KRW 4,655.00
+40.00 (0.87%)
At close: Mar 27, 2026
Jin Yang Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 22,287 | 29,694 | 12,659 | 12,308 | 9,538 |
Depreciation & Amortization | 2,409 | 2,024 | 2,655 | 2,291 | 2,154 |
Loss (Gain) From Sale of Assets | -31.33 | 77.14 | -0.86 | -24.9 | -9.53 |
Asset Writedown & Restructuring Costs | -29,000 | -24,919 | -2,263 | -3,556 | -1,451 |
Loss (Gain) From Sale of Investments | 112.38 | 621.53 | 9.65 | 97.96 | 13.48 |
Provision & Write-off of Bad Debts | 1,630 | -1,449 | 1,470 | 50.09 | -1,383 |
Other Operating Activities | 6,216 | 5,682 | 1,122 | 2,567 | 3,235 |
Change in Accounts Receivable | 1,446 | -2,755 | -2,754 | -918.28 | 132.24 |
Change in Inventory | -999.18 | 2,457 | -2,056 | -6,332 | -1,180 |
Change in Accounts Payable | -1,178 | 1,862 | -756.94 | 2,227 | -1,827 |
Change in Unearned Revenue | -40.5 | -30.13 | - | - | - |
Change in Other Net Operating Assets | -1,385 | -473.3 | -1,551 | -1,263 | -7,251 |
Operating Cash Flow | 1,465 | 12,792 | 8,534 | 7,448 | 1,971 |
Operating Cash Flow Growth | -88.55% | 49.91% | 14.58% | 277.96% | -68.44% |
Capital Expenditures | -4,266 | -90,060 | -682.28 | -3,218 | -2,516 |
Sale of Property, Plant & Equipment | 1.36 | 0.91 | 0.91 | 25.09 | 9.55 |
Sale (Purchase) of Intangibles | -1,563 | -397.44 | -851.25 | -1,423 | -207.08 |
Investment in Securities | -246.18 | 4,247 | 4,775 | -7,950 | -1,528 |
Other Investing Activities | -163.96 | -66.35 | -7 | -266.8 | -36.19 |
Investing Cash Flow | -6,385 | -86,276 | 3,236 | -12,833 | -4,278 |
Short-Term Debt Issued | 9,462 | - | - | - | - |
Long-Term Debt Issued | 5,585 | 76,500 | - | - | 16,000 |
Total Debt Issued | 15,047 | 76,500 | - | - | 16,000 |
Short-Term Debt Repaid | -9,462 | - | - | - | -6,000 |
Long-Term Debt Repaid | -1,480 | -4,756 | -5,678 | -189.12 | -129.92 |
Total Debt Repaid | -10,942 | -4,756 | -5,678 | -189.12 | -6,130 |
Net Debt Issued (Repaid) | 4,105 | 71,744 | -5,678 | -189.12 | 9,870 |
Issuance of Common Stock | 3,124 | - | - | - | - |
Repurchase of Common Stock | - | - | - | -2,574 | - |
Dividends Paid | -1,714 | -1,619 | -1,616 | -1,118 | -1,118 |
Other Financing Activities | -170 | 20 | -110 | -1,700 | 100 |
Financing Cash Flow | 5,344 | 70,145 | -7,404 | -5,581 | 8,852 |
Foreign Exchange Rate Adjustments | 0.03 | - | -0.68 | - | - |
Miscellaneous Cash Flow Adjustments | - | 0 | - | - | - |
Net Cash Flow | 423.93 | -3,338 | 4,365 | -10,966 | 6,544 |
Free Cash Flow | -2,801 | -77,268 | 7,851 | 4,230 | -545.86 |
Free Cash Flow Growth | - | - | 85.62% | - | - |
Free Cash Flow Margin | -2.32% | -68.18% | 8.34% | 5.55% | -0.87% |
Free Cash Flow Per Share | - | -6265.96 | 629.22 | 314.65 | -47.82 |
Cash Interest Paid | 2,160 | 1,132 | 19.46 | 14.53 | 87.13 |
Cash Income Tax Paid | 1,850 | 2,339 | 172.1 | 1,130 | 430.46 |
Levered Free Cash Flow | -6,198 | -80,264 | 2,805 | -1,894 | -4,291 |
Unlevered Free Cash Flow | -4,765 | -79,105 | 3,664 | -1,091 | -4,161 |
Change in Working Capital | -2,157 | 1,061 | -7,118 | -6,286 | -10,125 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.